ABVC Biopharma held annual shareholder meeting; quorum reached with 10.6 million shares represented by proxy

Reuters03-28
ABVC Biopharma held annual shareholder meeting; quorum reached with 10.6 million shares represented by proxy
  • ABVC BioPharma held its annual shareholder meeting on March 26, 2026.
  • Shareholders approved the re-election of 11 directors to the board.
  • Simon & Edward was ratified as the company’s independent registered public accounting firm for the year ending December 31, 2026.
  • An increase to the Amended and Restated 2016 Equity Incentive Plan to set the aggregate share reserve at 15% of issued and outstanding common stock as of the meeting date was approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-035499), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment